Skip to main content
Erschienen in: Wiener klinische Wochenschrift 11-12/2013

01.06.2013 | case report

Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases

verfasst von: Andreas Kronbichler, MD, Prof. Paul König, Martin Busch, MD, Prof. Gunter Wolf, Prof. Gert Mayer, Michael Rudnicki, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 11-12/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are common causes of nephrotic syndrome in children and adults. However, frequent relapses, steroid dependence, steroid resistance, and side effects of immunosuppressive therapy remain a therapeutic challenge. Rituximab (RTX) has evolved as an efficacious alternative in childhood MCD/FSGS. We report the effect of RTX in 5 adult patients with multirelapsing/steroid-dependent nephrotic syndrome due to MCD or FSGS.

Results

All five patients treated with RTX achieved sustained complete remission and additional immunosuppression was withdrawn. One patient had a relapse after 23 months, which was successfully treated with a further series of RTX infusion without reinitiation of steroid therapy. Serious adverse events related to RTX therapy were not observed in our patients.

Conclusions

Our results indicate that RTX is effective and cessation of additional immunosuppressants could be achieved in all patients reported in this study. RTX may be an effective alternative therapy in adult patients with multirelapsing/steroid-dependent nephrotic syndrome due to MCD or FSGS.
Literatur
1.
Zurück zum Zitat Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2(3):445–53.PubMedCrossRef Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2(3):445–53.PubMedCrossRef
2.
Zurück zum Zitat Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol. 2004;15(8):2169–77.PubMedCrossRef Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol. 2004;15(8):2169–77.PubMedCrossRef
3.
Zurück zum Zitat Huang JJ, Hsu SC, Chen FF, Sung JM, Tseng CC, Wang MC. Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis. Am J Nephrol. 2001;21(1):28–34.PubMedCrossRef Huang JJ, Hsu SC, Chen FF, Sung JM, Tseng CC, Wang MC. Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis. Am J Nephrol. 2001;21(1):28–34.PubMedCrossRef
4.
Zurück zum Zitat Philibert D, Cattran D. Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price? Nat Clin Pract Nephrol. 2008;4(10):550–9. Philibert D, Cattran D. Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price? Nat Clin Pract Nephrol. 2008;4(10):550–9.
5.
Zurück zum Zitat Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome study group. Kidney Int. 1999;56(6):2220–6.PubMedCrossRef Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome study group. Kidney Int. 1999;56(6):2220–6.PubMedCrossRef
6.
Zurück zum Zitat Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2002;17(11):2011–13.PubMedCrossRef Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2002;17(11):2011–13.PubMedCrossRef
7.
Zurück zum Zitat Al-Saran K, Mirza K, Al-Ghanam G, Abdelkarim M. Experience with levamisole in frequently relapsing, steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2006;21(2):201–5.PubMedCrossRef Al-Saran K, Mirza K, Al-Ghanam G, Abdelkarim M. Experience with levamisole in frequently relapsing, steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2006;21(2):201–5.PubMedCrossRef
8.
Zurück zum Zitat Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2012;27(5):1910–5.PubMedCrossRef Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2012;27(5):1910–5.PubMedCrossRef
9.
Zurück zum Zitat Prytula A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010;25(3):461–8.PubMedCrossRef Prytula A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010;25(3):461–8.PubMedCrossRef
10.
Zurück zum Zitat Hoxha E, Stahl RA, Harendza S. Rituximab in adult patients with immunosuppressive-dependent minimal chang. disease. Clin Nephrol. 2011;76(2):151–8.PubMedCrossRef Hoxha E, Stahl RA, Harendza S. Rituximab in adult patients with immunosuppressive-dependent minimal chang. disease. Clin Nephrol. 2011;76(2):151–8.PubMedCrossRef
11.
Zurück zum Zitat Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol. 2010;5(12):2207–12.PubMedCentralPubMedCrossRef Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol. 2010;5(12):2207–12.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Kisner T, Burst V, Teschner S, Benzing T, Kurschat CE. Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature. Nephron Clin Pract. 2012;120(2):c79–85.PubMedCrossRef Kisner T, Burst V, Teschner S, Benzing T, Kurschat CE. Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature. Nephron Clin Pract. 2012;120(2):c79–85.PubMedCrossRef
13.
Zurück zum Zitat Fernandez-Fresnedo G, Segarra A, Gonzalez E, Alexandru S, Delgado R, Ramos N, et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2009;4(8):1317–23.PubMedCentralPubMedCrossRef Fernandez-Fresnedo G, Segarra A, Gonzalez E, Alexandru S, Delgado R, Ramos N, et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2009;4(8):1317–23.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Sugiura H, Takei T, Itabashi M, Tsukada M, Moriyama T, Kojima C, et al. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract. 2011;117(2):c98–105.PubMedCrossRef Sugiura H, Takei T, Itabashi M, Tsukada M, Moriyama T, Kojima C, et al. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract. 2011;117(2):c98–105.PubMedCrossRef
15.
Zurück zum Zitat Ochi A, Takei T, Nakayama K, Iwasaki C, Kamei D, Tsuruta Y, et al. Rituximab treatment for adult patients with focal segmental glomerulosclerosis. Intern Med. 2012;51(7):759–62.PubMedCrossRef Ochi A, Takei T, Nakayama K, Iwasaki C, Kamei D, Tsuruta Y, et al. Rituximab treatment for adult patients with focal segmental glomerulosclerosis. Intern Med. 2012;51(7):759–62.PubMedCrossRef
17.
Zurück zum Zitat Peters HP, van de Kar NC, Wetzels JF. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosi: report of four cases and review of the literature. Neth J Med. 2008;66(10):408–15.PubMed Peters HP, van de Kar NC, Wetzels JF. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosi: report of four cases and review of the literature. Neth J Med. 2008;66(10):408–15.PubMed
18.
Zurück zum Zitat Yang T, Nast CC, Vo A, Jordan SC. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant. 2008;23(1):377–80.PubMedCrossRef Yang T, Nast CC, Vo A, Jordan SC. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant. 2008;23(1):377–80.PubMedCrossRef
19.
Zurück zum Zitat Francois H, Daugas E, Bensman A, Ronco P. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis. 2007;49(1):158–61.PubMedCrossRef Francois H, Daugas E, Bensman A, Ronco P. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis. 2007;49(1):158–61.PubMedCrossRef
20.
Zurück zum Zitat Beco A, Castro-Ferreira I, Coentrao L, Neto R, Sampaio S, Pestana M. Rituximab for steroid-dependent nephrotic syndrome. Clin Nephrol. 2010;74(4):308–10.PubMed Beco A, Castro-Ferreira I, Coentrao L, Neto R, Sampaio S, Pestana M. Rituximab for steroid-dependent nephrotic syndrome. Clin Nephrol. 2010;74(4):308–10.PubMed
21.
Zurück zum Zitat Kurosu N, Sugiura H, Iwasaki C, Asamiya Y, Kojima C, Moriyama T, et al. Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome. Intern Med. 2009;48(21):1901–04.PubMedCrossRef Kurosu N, Sugiura H, Iwasaki C, Asamiya Y, Kojima C, Moriyama T, et al. Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome. Intern Med. 2009;48(21):1901–04.PubMedCrossRef
22.
Zurück zum Zitat Amemiya N, Takei T, Kojima C, Nokiba H, Itabashi M, Nitta K. Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome. Clin Exp Nephrol. 2011;15(6):933–6.PubMedCrossRef Amemiya N, Takei T, Kojima C, Nokiba H, Itabashi M, Nitta K. Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome. Clin Exp Nephrol. 2011;15(6):933–6.PubMedCrossRef
23.
Zurück zum Zitat Bitzan M, Anselmo M, Carpineta L. Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature. Pediatr Pulmonol. 2009;44(9):922–34.PubMedCrossRef Bitzan M, Anselmo M, Carpineta L. Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature. Pediatr Pulmonol. 2009;44(9):922–34.PubMedCrossRef
24.
Zurück zum Zitat Datta SK. Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells. Nat Clin Pract Rheumatol. 2009;5(2):80–2.PubMedCentralPubMedCrossRef Datta SK. Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells. Nat Clin Pract Rheumatol. 2009;5(2):80–2.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3(85):85ra46. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3(85):85ra46.
26.
Zurück zum Zitat Wilk E, Witte T, Marquardt N, Horvath T, Kalippke K, Scholz K, et al. Depletion of functionally active CD20 + T cells by rituximab treatment. Arthritis Rheum. 2009;60(12):3563–71.PubMedCrossRef Wilk E, Witte T, Marquardt N, Horvath T, Kalippke K, Scholz K, et al. Depletion of functionally active CD20 + T cells by rituximab treatment. Arthritis Rheum. 2009;60(12):3563–71.PubMedCrossRef
27.
Zurück zum Zitat Meyrier AY. Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis? Kidney Int. 2009;76(5):487–91.PubMedCrossRef Meyrier AY. Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis? Kidney Int. 2009;76(5):487–91.PubMedCrossRef
28.
Zurück zum Zitat Kanai T, Shiraishi H, Yamagata T, Ito T, Odaka J, Saito T, et al. Th2 cells predominate in idiopathic steroid-sensitive nephrotic syndrome. Clin Exp Nephrol. 2010;14(6):578–83.PubMedCrossRef Kanai T, Shiraishi H, Yamagata T, Ito T, Odaka J, Saito T, et al. Th2 cells predominate in idiopathic steroid-sensitive nephrotic syndrome. Clin Exp Nephrol. 2010;14(6):578–83.PubMedCrossRef
Metadaten
Titel
Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases
verfasst von
Andreas Kronbichler, MD
Prof. Paul König
Martin Busch, MD
Prof. Gunter Wolf
Prof. Gert Mayer
Michael Rudnicki, MD
Publikationsdatum
01.06.2013
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 11-12/2013
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-013-0366-7

Weitere Artikel der Ausgabe 11-12/2013

Wiener klinische Wochenschrift 11-12/2013 Zur Ausgabe